Armata Pharmaceuticals, Inc. (ARMP)
Develops bacteriophage treatments for antibiotic-resistant bacterial infections
$4.73-0.08%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago+86.2%
The outlook
Armata Pharmaceuticals has strong analyst support with both analysts rating it a Buy, and the average price target sits roughly 270% above the current price. The stock is trading well below its 50- and 200-day moving averages and sits near the lower end of its 52-week range, reflecting a weak near-term trend despite bullish longer-term sentiment.
What’s behind the score
Analyst consensusStrong Buy — 1.0 avg of 2 analysts
Price trendBelow its 50- & 200-day averages
52-week range17% of the way from its 52-week low to high
Price targetAvg target +270% vs current price
Analyst price target
~12-month · 2 analysts$17.50average target+270.0% vs now
Now $4.73
Low $15.00High $20.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$173.6M
52-wk high
$16.34
52-wk low
$2.36
50-day avg
$6.51
200-day avg
$7.53
Trailing P/E
—